Our results revealed that two functional polymorphisms of XRCC1 may have prognostic value of NSCLC patients under platinum-based chemotherapy, but they are still far away from clinical practice, since many genes in other pathways, apart from the BER pathway, also contribute to the sensitivity to platinum drugs 53. The gene discussed is XRCC1; the disease is non-small cell lung carcinoma.